We thank the reviewer for pointing this was not clear. As mentioned in the statistical analysis sub-section within the methods part, all in vitro experiments were repeated at least 3 times, and so depicted We have now added this also to the legends of figures 1, 2, and 3. Per the in vivo study, as was mentioned in the methods (sub-section 2.8), 52 animals were included in the study. The specific numbers in each treatment group are now mentioned in the results (sub-section 3.4): “During the treatment period, average tumor volumes of control animals (n = 11) increased 5.9-fold (Figure 4b and 4c; and Figure S3 for tumor images). For animals treated with TTFields (n = 15) or sorafenib (n = 10), tumor growth was significantly lower, 3.3- and 2.3-fold, respectively. In the TTFields-sorafenib combination group (n = 16), a 1.6-fold increase in tumor volume within the treatment period was observed, a growth significantly lower than that for control or for each treatment alone.” It is also mentioned in the legend of figure 4: “Rats (n = 52) were inoculated orthotopically with rat HCC N1S1 cells, and treated with sham-vehicle (n = 11), TTFields alone (n = 15), sorafenib alone (n = 10), or TTFields + sorafenib (n = 16), according to the depicted timeline (a).” Point 3: LC3 is increased in all the groups except in control tissue, however, cell death was increased only in combined group.
The apoptosis marker cleaved PARP displayed increased expression in the combined group already after 24 hours, elevating even further after 48 hours of treatment.